Sanofi India Limited , a prominent player in the pharmaceutical sector, has released its financial results for the third quarter ended September 30. The company demonstrated mixed performance, with improved profitability margins despite a decline in revenue and net profit.

Financial Highlights

Key Takeaways

1. Revenue Decline: Sanofi India experienced a year-over-year decrease in revenue from ₹524.00 crore to ₹475.40 crore, representing a decline of 9.30%.

2. Improved EBITDA: Despite the revenue drop, the company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased from ₹120.00 crore to ₹134.00 crore, showing a growth of 11.67%.

3. EBITDA Margin Expansion: The EBITDA margin saw a significant improvement, rising from 23.00% to 28.00%, indicating enhanced operational efficiency.

4. Net Profit Decrease: The company's net profit declined from ₹82.00 crore to ₹76.00 crore, a decrease of 7.32% compared to the same quarter last year.

Corporate Actions and Strategy

1. Interim Dividend: The Board declared an interim dividend of ₹75 per equity share. The record date for this dividend is set for November 7.

2. Portfolio Streamlining: Sanofi India is focusing on streamlining its portfolio to concentrate on core therapeutic areas, including diabetes and cardiovascular treatments.

3. Cost Efficiency: The company's improved EBITDA and operating margin are attributed to cost efficiency measures and a favorable product mix.

Market Performance

Following the results announcement, Sanofi India's shares remained largely unchanged at ₹4,747.00. The stock has gained 22% year-to-date, indicating overall positive investor sentiment despite the mixed quarterly results.

The mixed results reflect the challenging environment in which Sanofi India operates. While the company has managed to improve its operational efficiency, as evidenced by the higher EBITDA and margin, the decline in revenue and net profit indicates ongoing market pressures.

Investors and stakeholders will likely be watching closely to see how Sanofi India's strategic moves, such as portfolio streamlining and cost efficiency measures, will impact its performance in the coming quarters. The company's ability to maintain its improved margins while addressing the revenue decline will be crucial for its future financial health.

Sanofi India Limited (SIL), a prominent player in the pharmaceutical industry, has announced significant changes in its leadership team, specifically in the role of Company Secretary and Compliance Officer.

Resignation of Arjun Thakkar

Mr. Arjun Thakkar, the current Company Secretary and Compliance Officer of Sanofi India Limited, has tendered his resignation effective September 30, 2025. Thakkar's decision to step down comes as he pursues a new career opportunity within the Sanofi Group, specifically in the Ethics & Business Integrity department.

The company has expressed its appreciation for Thakkar's contributions during his tenure. With his departure, Thakkar will also cease to be a Key Managerial Personnel and Senior Management Personnel of the company.

Appointment of Haresh Vala

In light of this transition, the Board of Directors of Sanofi India Limited, upon recommendation from the Nomination and Remuneration Committee, has approved the appointment of Mr. Haresh Vala as the new Company Secretary and Compliance Officer. Vala's appointment will be effective from October 1, 2025.

About Haresh Vala

Mr. Haresh Vala brings a wealth of experience to his new role at Sanofi India Limited:

• Professional Qualifications: Associate Member of the Institute of Company Secretaries of India
• Experience: Over two decades in corporate secretarial and compliance functions across diverse industries
• Education: Holds degrees in Law and Commerce from the University of Mumbai
• Expertise: Deep knowledge in corporate governance, regulatory compliance, investor relations, SEBI regulations, and Companies Act compliances
• Key Skills: Experienced in entity formation, capital structuring, fund-raising, dividend distribution, related party transactions, and compliance with LODR regulations

Vala's appointment is expected to strengthen Sanofi India's corporate governance framework and ensure compliance with regulatory requirements.

Additional Responsibilities

The Board has also authorized Mr. Haresh Vala to determine the materiality of events or information and make disclosures to the Stock Exchanges, in addition to other authorized Key Managerial Personnel. This responsibility is in line with Regulation 30(5) of the SEBI Listing Regulations.

Board Meeting Details

The decision regarding these leadership changes was made during a Board of Directors meeting held on September 25, 2025. The meeting commenced at 4:15 p.m. and concluded at 4:45 p.m.

These leadership changes at Sanofi India Limited reflect the company's commitment to maintaining strong corporate governance and ensuring smooth transitions in key roles. As the pharmaceutical industry continues to evolve, such strategic appointments are crucial for navigating regulatory landscapes and driving organizational growth.